These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. Wolfe CM; Green WH; Cognetta AB; Hatfield HK Dermatol Surg; 2012 Nov; 38(11):1863-6. PubMed ID: 22805146 [No Abstract] [Full Text] [Related]
3. Oral hedgehog-pathway inhibitors for basal-cell carcinoma. Lear JT N Engl J Med; 2012 Jun; 366(23):2225-6. PubMed ID: 22670909 [No Abstract] [Full Text] [Related]
4. Vismodegib in advanced basal-cell carcinoma. Henkin RI N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271 [No Abstract] [Full Text] [Related]
5. Developing expert consensus for the use of hedgehog inhibitors in basal cell nevus syndrome. Lukowiak TM; Cahn B; Samie F; Leffell DJ; Oro A; Kibbi N; Kheterpal M; Babakoohi S; Khushalani NI; Stephenson A; Ma MS; Shi VJ; Ahmed A; Koza E; Haq M; Yi MD; Nadir U; Yoo S; Brieva JC; Lucas J; Haber R; Alam M Arch Dermatol Res; 2024 Jul; 316(7):453. PubMed ID: 38967654 [No Abstract] [Full Text] [Related]
6. 9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient. Kieny A; Kremer V; Scheidecker S; Lipsker D Acta Derm Venereol; 2018 Feb; 98(2):287-288. PubMed ID: 29057423 [No Abstract] [Full Text] [Related]
7. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. Tang JY; Mackay-Wiggan JM; Aszterbaum M; Yauch RL; Lindgren J; Chang K; Coppola C; Chanana AM; Marji J; Bickers DR; Epstein EH N Engl J Med; 2012 Jun; 366(23):2180-8. PubMed ID: 22670904 [TBL] [Abstract][Full Text] [Related]
8. Effect of Calcium Channel Blockade on Vismodegib-Induced Muscle Cramps. Ally MS; Tang JY; Lindgren J; Acosta-Raphael M; Rezaee M; Chanana AM; Epstein EH JAMA Dermatol; 2015 Oct; 151(10):1132-4. PubMed ID: 26200175 [No Abstract] [Full Text] [Related]
9. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome. Chang AL; Atwood SX; Tartar DM; Oro AE JAMA Dermatol; 2013 May; 149(5):639-41. PubMed ID: 23677114 [No Abstract] [Full Text] [Related]
10. Targeting the hedgehog pathway to treat basal cell carcinoma. Geeraert P; Williams JS; Brownell I J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945 [TBL] [Abstract][Full Text] [Related]
11. Comment on basal cell carcinoma rebound after cessation of vismodegib in an individual with basal cell nevus syndrome. Ally MS; Wysong A; Tang JY; Aasi S Dermatol Surg; 2013 Sep; 39(9):1413-4. PubMed ID: 23682843 [No Abstract] [Full Text] [Related]